Introduction
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (Hirtz et al., 2007) , with close to 5 million individuals affected worldwide and expectations for this number to double by 2030 (Dorsey et al., 2007) . First described as a ''shaking palsy'' by James Parkinson 200 years ago, it is now recognized as a complex and heterogeneous disorder that encompasses the classic motor features (bradykinesia, rigidity, and tremor) as well as early and late non-motor manifestations (Marras and Chaudhuri, 2016) . Dopaminergic drugs, especially levodopa therapy, provide symptomatic benefit and improvement of quality of life but are typically associated with motor fluctuations, dyskinesias, and non-motor complications (Kalia and Lang, 2015; Martínez-Ferná ndez et al., 2016) . Importantly, no available treatment is currently able to modify disease progression Lang and Espay, 2018) .
The pathognomonic hallmark of PD is the neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) leading to striatal dopamine depletion, which in turn is causally responsible for the cardinal motor features, particularly rigidity and bradykinesia. The other histological characteristic of PD is the presence, in remaining neurons, of Lewy body inclusions and Lewy neurites (Dauer and Przedborski, 2003; Jellinger, 2012) , collectively referred to as Lewy pathology. A major emphasis has been placed over several decades on understanding the neurodegeneration of the nigrostriatal projection and motor features of PD. However, it is now widely realized that PD evolves into a multi-systems disorder that extends beyond the SNc, affecting both central and peripheral nervous systems Coon et al., 2018) accompanied by a wide variety of non-motor symptoms, some of which may be present before the onset of the motor features (Schapira et al., 2017) . This wider understanding of PD clinical characteristics fits well with the now popular Braak et al. hypothesis, based on the recognition of Lewy pathology as an essential pathogenic feature and on the propagation of alpha-synuclein toxic species from the peripheral nervous system and olfactory bulb through the brain in a bottom-up caudo-rostral direction up to the neocortex (Braak et al., 2003 (Braak et al., , 2006 Del Tredici and Braak, 2016) . This concept of bottom-up propagation of Lewy pathology has become so widely accepted that its conjectural induction-based nature and the growing evidence against its universal applicability Ulusoy et al., 2017) are too often neglected. Indeed, the mechanisms underlying the postulated propagation are still hotly debated, and the actual relationship between Lewy pathology and neuronal death remains unclear (Surmeier et al., 2017) .
Despite numerous advances , the etiopathogenesis of PD remains to be unraveled. PD is currently understood mainly as the result of a multi-factorial interplay of genetic, lifestyle, and environmental factors, with aging as a major determinant Kalia and Lang, 2015; Collier et al., 2017) . In this Perspective, we would like to propose a different but complementary, rather than alternative, view concerning the mechanisms involved in the onset and progression of neurodegeneration in PD. We put forward the notion that the neocortex is not necessarily the final stage of a bottom-up sequence, but could also be an initial top-down contributor for ''pushing over the edge'' the vulnerable dopaminergic neurons.
The rationale for this cortical pathogenesis is based upon a few principal aspects of the neurodegeneration process in PD. First, the cardinal motor features are typically circumscribed to one body part at disease onset, progressing slowly to involve adjacent body segments and the contralateral hemibody over the years. In clinical neurology, focal signs (once a peripheral nervous system disorder has been ruled out) derive most often from lesion/dysfunction of somatotopically organized structures, e.g., the thalamus, the cerebellum, and, most notably, the neocortex. Second, striatal dopaminergic denervation is greater than SNc loss in early disease evolution and typically occurs first and most severely in the posterior (motor) putamen (Kordower et al., 2013) . Thus, even though a primary origin in the soma remains plausible, the striatal onset of nigrostriatal loss points toward a retrograde degeneration of dopaminergic neurons starting from striatal axon terminals (Cheng et al., 2010; Uchihara and Giasson, 2016; Volpicelli-Daley, 2017) . Third, even if it could be eventually demonstrated that alpha-synuclein toxic species spread up from the periphery and play a causal role in neurodegeneration, the initial focal nature of synaptic and neuronal loss in the dopaminergic nigrostriatal projection responsible for the focal motor onset would still require a complementary explanation.
Accordingly, we propose that corticostriatal activity over a lifespan-specifically in motor areas projecting to the posterior putamen such as the primary motor cortex (area 4), premotor (area 6) and supplementary motor area (Alexander et al., 1986; Nambu et al., 2002 )-represents a critical somatotopic ''stressor'' contributing to striatal dysfunction, starting from the motor putamen and ultimately leading to retrograde neurodegeneration of nigrostriatal neurons in the ventro-lateral SNc region, and focal motor onset of Parkinson's disease.
Evidence for Primary Cortical Involvement in Parkinson's Disease Focal Onset of Motor Signs
Possibly the strongest support for the cortical pathogenesis of PD is the clinical paradox based on the ubiquitous-but often underappreciated-observation of a focal onset of parkinsonian signs (e.g., reduced arm swinging, hand tremor, leg dragging, etc.), which is later associated with a somatotopically related corporal involvement of levodopa-induced dyskinesias (Luquin et al., 1992; Vidailhet et al., 1994) . This motor focality ostensibly contrasts with the immense axonal arborization and profuse synaptic density of striatal dopaminergic terminals (Matsuda et al., 2009; Bolam and Pissadaki, 2012) and with the lack of recognized somatotopic arrangement in the SNc (Parent et al., 1983; Matsuda et al., 2009; Nambu, 2011) . Thus, focal motor signs in PD could be better explained by considering the topographic and somatotopic organization of corticostriatal projections in non-human and human primates (Lehé ricy et al., 1998; Maillard et al., 2000; Nambu et al., 2002; Gerardin et al., 2003; Nambu, 2011) . Admittedly, a non-somatotopic SNc degeneration leading to focal symptomatology by affecting somatotopically organized striatal regions via stochastic threshold-based mechanisms, including region-specific sensitivity to dopamine loss and other compensatory processes (Blesa et al., 2017) , cannot be formally excluded on the basis of the data currently available. However, a direct role of cortico-putaminal projections probably offers a more parsimonious alternative explanation for the focal motor onset of PD.
As a consequence of this clinical focal onset, the evolution of PD is typically asymmetric between body sides (Pagano et al., 2016) . Some evidence indicates that handedness significantly correlates with the most affected side (van der Hoorn et al., 2012; Scherfler et al., 2012; Pagano et al., 2016) . Interestingly, the predominance of right-handedness is considerably more developed in humans than in non-human primates and likely reflects the hemispheric specialization of the left cerebral cortex for manual motor skills and language (Fitch and Braccini, 2013; Meguerditchian et al., 2013; Papadatou-Pastou and Sá fá r, 2016) . The relationship between laterality and parkinsonian symptomatology is probably more complex than currently recognized, as the emphasis on handedness leaves out the possible contributions of footedness and also of visual and auditory dominance (Tran et al., 2014) . Nonetheless, the available data suggest that cortex-dependent behavioral preference might influence the asymmetric onset of nigrostriatal neurodegeneration. Prodromal Cortical Abnormalities in Early Parkinson's Disease From the viewpoint of a caudo-rostral progression, prodromal cortical alterations may be interpreted as a dualistic interplay between the extension of pathophysiological abnormalities (Braak's) and compensatory mechanisms (Appel-Cresswell et al., 2010; Martinu and Monchi, 2013; Blesa et al., 2017) . On the other hand, from our top-down perspective, all prodromal cortical alterations become potential pathogenic mechanisms.
Some direct evidence for cortical abnormalities being prodromal to the motor symptomatology may come from studies on early, highly asymmetric PD patients, in whom the symptomatic and the pre-symptomatic side of the brain are investigated separately with transcranial magnetic stimulation (TMS) and noninvasive brain stimulation techniques. TMS of the primary motor cortex elicits motor-evoked potentials that can be electromyographically recorded at the target muscle to separately assess, with specific stimulation protocols, both corticospinal and intracortical excitability (Hallett, 2007) . Non-invasive brain stimulation techniques, on the other hand, perturb cortical circuits to induce long-lasting plasticity that resembles the long-term potentiation and depression (LTP/LTD) of synaptic strength observed in animal models (Hallett, 2007; Polanía et al., 2018) . In highly asymmetric PD patients, the symptomatic motor cortex is characterized by a loss of intracortical inhibition (Kojovic et al., 2012 (Kojovic et al., , 2015 , possibly a compensatory mechanism (Blesa et al., 2017) , and a loss of LTP/LTD-like plasticity induced by non-invasive brain stimulation techniques (Kishore et al., 2012; Kojovic et al., 2012 Kojovic et al., , 2015 , which is consistent with cortical findings obtained in animal models of dopamine depletion (Paillé et al., 2010; Hsieh et al., 2015; Guo et al., 2015; Schirinzi et al., 2016; Becker et al., 2018) . Conversely, the pre-symptomatic motor cortex exhibits minimal if any alterations of corticospinal and intracortical excitability (Kojovic et al., 2012 (Kojovic et al., , 2015 , but important alterations of cortical plasticity. Namely, loss of LTP/LTD-like plasticity induced by theta-burst stimulation (Kishore et al., 2012) and enhanced plasticity induced by paired-associative stimulation (Kojovic et al., 2012) have been recognized. Despite the relatively small sample size of these studies and the intrinsic variability of plasticity effects induced by non-invasive brain stimulation techniques (Polanía et al., 2018) , alterations in cortical plasticity seem to develop prior to the alterations in cortical excitability and the appearance of motor manifestations in PD.
The normal TMS-induced corticospinal excitability in the prodromal phase is consistent with the normal pyramidal cells and negligible synuclein pathology observed in the primary motor cortex and motor thalamus-although significant loss of cortico-cortical projecting pyramidal neurons was detected in the pre-supplementary motor area (pre-SMA)-in a small group of PD patients examined pathologically after a relatively short disease evolution (MacDonald and Halliday, 2002; Halliday et al., 2005) . On the other hand, prodromal alterations in motor cortex plasticity are supported by pathological investigations on Ca 2+ channels, which are critical in the regulation of cortical excitability and plasticity (Wankerl et al., 2010; Verhoog et al., 2013; Weise et al., 2017) . Specifically, recent postmortem studies show increased expression of L-type voltagegated Ca 2+ channels in the primary motor cortex at least as early as Braak's stages III-IV (Hurley et al., 2013 (Hurley et al., , 2015b , and molecular alterations in motor cortical areas have also been reported in incidental Lewy body disease at Braak's stages I-II (Hurley et al., 2015a; Santpere et al., 2018) . Motor cortical areas thus seem to be altered well before the appearance of cortical Lewy pathology (Braak's stages V-VI) and before the onset of motor features in PD. It is also noteworthy here that aging, the main risk factor for nigrostriatal degeneration (Collier et al., 2017) , is also associated with decreased motor cortex plasticity (Freitas et al., 2011) and impaired corticostriatal plasticity (Walsh and Ou, 1994; Akopian and Walsh, 2006) . In any event, whether or not these alterations may precede SNc neuronal loss in PD remains unclear. Importantly, prodromal cortical alterations that develop as a consequence of the initial dopaminergic loss, but before the onset of clinical motor features, may still play a relevant role in the subclinical motor progression and the focal motor onset of the disease.
Phylogenesis of the Cerebral Cortex
Animals, including non-human primates, have not thus far been recognized to develop idiopathic PD, and the most distinguishing evolutionary aspect that differentiates humans from animals is an overdeveloped cerebral cortex (Northcutt and Kaas, 1995; Hofman, 2014) . The total number of cortical neurons is in the order of tens of millions in rats, billions (i.e., 10 9 ) in non-human primates, and tens of billions in humans (Azevedo et al., 2009) , with an exponential increment in the ratio of cortical-to-striatal neurons from about few-to-one in rats to hundreds-to-one in humans (Oorschot, 1996; Kreczmanski et al., 2007; Wegiel et al., 2014) . Recent data suggest that the striatum is actually evolutionarily decreasing in humans compared to non-human primates (Barger et al., 2014) . Evolution might thus have packed the human brain with increased convergence of cortical projections to individual striatal neurons and nigrostriatal axons compared to other species. A high density of pre-synaptic corticostriatal inputs onto striatal neurons and dopaminergic synaptic arborization could thus be another propitiatory factor in the pathogenesis of PD.
Cortical Pathogenic Mechanisms of Nigrostriatal Degeneration
The caudal (posterior) putamen is the site of greatest dopaminergic depletion in early PD (Kish et al., 1988; Pavese and Brooks, 2009) (Figure 1A ). This striatal region is mainly engaged in movement control and, particularly, in habitual behavior (Redgrave et al., 2010) ( Figure 1B) . Indeed, impairment of automatic movements (e.g., arm swinging, eye-blinking, turning in bed, etc.) and habitual performance (e.g., writing, walking, dressing, etc.) are very common early motor manifestations of PD, even antedating the diagnosis by some years (Darweesh et al., 2017) . Motor-related performance is arguably the most common human activity and, by and large, adult human life is made of habitual behaviors. Accordingly, corticostriatal activity onto the posterior putamen sustains frequent regular engagement in daily life. How could this activity become a relevant etiopathogenic mechanism to explain nigrostriatal neurodegeneration in PD?
The core of our proposal lies in two principal features, namely the fine anatomo-functional topography of corticostriatal projections on the one hand, and the paramount role of alpha-synuclein in PD neurodegeneration process on the other.
Corticostriatal Organization and Functional Anatomy
The striatum is richly innervated by cortical and thalamic glutamatergic afferents. The cortex projects to the striatum in a topographically organized rostro-caudal fashion ( Figure 1B ). In concrete, the sensorimotor cortex (areas 1, 3a, 3b, 4, 6, SMA) projects to the posterior (motor) putamen in a somatotopically organized manner Graybiel, 1991, 1993; Lehé ricy et al., 1998; Maillard et al., 2000; Nambu et al., 2002; Gerardin et al., 2003; Nambu, 2011;  Figure 1C ), whereas the pre-frontal cortex projects to the head of the caudate, the dorsolateral prefrontal cortex and pre-SMA project to the anterior putamen, and the ventral striatum is connected with limbic areas in segregated fashion but with no somatotopic organization (Alexander et al., 1986) . Corticostriatal afferents are mainly glutamatergic and excitatory (Wilson, 1987) and project heavily onto GABAergic medium spiny neurons (MSNs). MSNs also receive glutamatergic thalamostriatal afferents mainly from the centromedian and parafascicularis nuclei (Smith et al., 2014a) . Compared to corticostriatal projections, however, thalamostriatal afferents are less prominent and are not somatotopically organized (HuertaOcampo et al., 2014; Smith et al., 2014a) . Nigrostriatal input exerts not only the classic receptor-dependent post-synaptic neuromodulation of MSN excitability (Gerfen and Surmeier, 2011) , but also pre-synaptic inhibition of glutamate striatal release via dopaminergic receptors on corticostriatal terminals in an activity-dependent fashion (Bamford et al., 2004) . MSN excitability is also influenced and modulated by striatal cholinergic and GABAergic interneurons (Tepper et al., 2004; Faust et al., 2016) , which control striatal output activity particularly in the sensorimotor striatum (Kulik et al., 2017) and are also modulated by dopaminergic input (Momiyama and Nishijo, 2017) . Altogether, corticostriatal and nigrostriatal axons interact at the synaptic level forming a functional unit with MSNs and interneurons (Shipp, 2017) . Accordingly, striatal synaptic alterations in animal models of nigrostriatal degeneration are not limited to nigrostriatal dopaminergic terminals, but invariably include corticostriatal glutamatergic synapses (Paillé et al., 2010; Villalba et al., 2015; Calo et al., 2016; Schirinzi et al., 2016) .
Cortical Control of Striatal Dopamine Release
The existence of focal top-down mechanisms of cortical control on nigrostriatal function is supported by experimental and human studies demonstrating that cortical excitability topographically modulates striatal dopamine release (Ko and Strafella, 2012). Early work in rats showed that enhancing prefrontal cortex neuronal activity by direct injection of glutamate increased burst firing of dopamine cells in the ventral tegmental area (VTA) and enhanced dopamine release in the nucleus accumbens, whereas injecting the local anesthetic lidocaine induced the opposite effects (Murase et al., 1993) . Topography-specific effects on striatal dopamine release were then obtained by electrical stimulation (Taber and Fibiger, 1993) Kanno et al., 2004) , and optogenetic stimulation of the motor cortex (Kosillo et al., 2016) . These results were confirmed in healthy human subjects, in whom increasing cortical excitability with rTMS increases the release of striatal dopamine as measured with [(11)C]raclopride positron emission tomography (PET) (Ko and Strafella, 2012) . Importantly, when rTMS was applied to the prefrontal cortex, striatal dopamine increased in the caudate nucleus (Strafella et al., 2001 ), whereas if rTMS was applied to the primary motor cortex, striatal dopamine increased in the putamen (Strafella et al., 2003) , demonstrating in human subjects the segregated topography of corticostriatal projections and its interaction with nigrostriatal dopamine release.
This cortical control of striatal dopamine release might be mediated, at least in principle, by monosynaptic cortico-nigral excitation, or disynaptic cortico-subthalamo-nigral excitation through the ''hyperdirect'' pathway (Monakow et al., 1978; Hammond et al., 1978; Nambu, 2004) . However, direct projections from the cortex to the SNc are extremely scarce in primates (Frankle et al., 2006) , and the lack of somatotopic organization of the nigrostriatal projection makes it unlikely that the firing of specific neuronal groups in the SNc can sustain a fine topographic control of dopamine release in the striatum. Instead, recent data suggest that striatal dopamine can be released through corticostriatal and thalamostriatal activation of cholinergic interneurons, in turn activating nicotinic receptors on dopaminergic axons (Threlfell et al., 2012; Kosillo et al., 2016 ; Figure 1D ). Corticostriatal activity can thus play a key role in driving focal dopamine release at nigrostriatal terminals. Corticostriatal Release of Alpha-Synuclein Nigrostriatal dopaminergic cells are characterized by a highly divergent axonal arborization (Matsuda et al., 2009; Bolam and Pissadaki, 2012; Pacelli et al., 2015) and a bioenergetically demanding combination of intrinsic physiological properties that bring them to a ''metabolic edge'' for mitochondrial oxidant stress and proteostatic dysfunction (Surmeier et al., 2017) . Mitochondrial dysfunction has been associated with alpha-synuclein aggregation and degeneration of the nigrostriatal projection (Mullin and Schapira, 2013) . Interestingly, in both wild-type and alpha-synuclein overexpressing transgenic mice, a substantial amount-if not the majority-of physiological alpha-synuclein in the striatum is localized at corticostriatal glutamatergic terminals (Totterdell and Meredith, 2005; Taguchi et al., 2016; Emmanouilidou et al., 2016; Figures 2A and 2B) . Conversely, virtually no alpha-synuclein is detected in the cell bodies of the output cortical layers V and VI (Taguchi et al., 2016) , and, importantly, relatively little alpha-synclein is localized at thalamostriatal and nigrostriatal terminals (Emmanouilidou et al., 2016;  Figure 2B ). Presynaptic corticostriatal alpha-synuclein is secreted to the striatal extracellular space, possibly via exosomes (Emmanouilidou et al., 2010; Alvarez-Erviti et al., 2011; Lee et al., 2014) , by increasing the concentration of intracellular Ca 2+ (Emmanouilidou et al., 2016; Figure 2C ). Influx of Ca 2+ in the presynaptic intracellular space is also a key element of synaptic transmission, through activation of voltage-gated Ca 2+ channels by axonal depolarization (Schneggenburger and Neher, 2000; Nanou and Catterall, 2018) . Corticostriatal activity may thus determine both neurotransmitter release and alpha-synuclein secretion. In fact, recent experiments show that extracellular alpha-synuclein levels are directly regulated by neuronal activity (Yamada and Iwatsubo, 2018) , similarly to what was previously observed for tau (Yamada et al., 2014) and amyloid beta (Cirrito et al., 2005; Bero et al., 2011) . In turn, striatal extracellular alphasynuclein also leads to dopamine release by activating presynaptic Ca v 2.2 channels at nigrostriatal terminals (Ronzitti et al., 2014) . Corticostriatal activity (possibly jointly with thalamostriatal activity) thus likely represents a crucial state-dependent regulator of striatal levels of both dopamine and alpha-synuclein. Dopamine-Dependent Alpha-Synuclein Oligomerization Physiological alpha-synuclein exists predominantly as a soluble monomer in dynamic equilibrium between different conformational and/or oligomeric states (Lashuel et al., 2013; Ghiglieri et al., 2018) . When this dynamic equilibrium stabilizes toward formation of oligomers and protofibrils, alpha-synuclein seems to become particularly toxic for neurons (Lashuel et al., 2013; Ghiglieri et al., 2018) . Consequently, it needs to be determined how physiological alpha-synuclein monomers secreted by corticostriatal activity may contribute to oligomerization, toxicity, and neurodegeneration at striatal level at the early stages of PD. Even though secreted monomeric alpha-synuclein per se may exhibit toxicity to cells (Emmanouilidou et al., 2010; Lee et al., 2014) , a key neurotoxic role seems to be played by dopamine. In both cell-free and cellular model systems, oxidized dopamine kinetically stabilizes toxic alpha-synuclein oligomers (Conway et al., 2001; Mazzulli et al., 2006; Mazzulli et al., 2007) . Similarly, endogenous dopamine production is required for the accumulation of soluble alpha-synuclein protein complexes to become neurotoxic in cultured human dopaminergic neurons (Xu et al., 2002) . Recent findings in vivo suggest that it is this very combination of high levels of both alpha-synuclein and dopamine that promotes alpha-synuclein oligomerization and nigrostriatal degeneration (Mor et al., 2017 ; Figure 2D ).
Cortical Pathogenesis of Nigrostriatal Degeneration
Based on the data available so far, we propose that corticostriatal activity may act as a top-down somatotopic stressor for nigrostriatal neurons ( Figure 3A) . Specifically, we envisage that increased corticostriatal activity onto the caudal putamen facilitates the local milieu for increased extracellular levels of alphasynuclein to become toxic upon axonal dopaminergic endings ( Figure 3B ). This mechanism would probably be potentiated by aging and associated with other putative pathogenic factors (i.e., mitochondrial dysfunction, etc.), together setting the scenario to initiate and promote alpha-synuclein aggregation, focal impairment of nigrostriatal axonal endings, restricted putaminal dopamine depletion, and ultimately retrograde nigrostriatal degeneration and Lewy body accumulation in the soma of ventro-lateral SNc neurons. This notion would explain the selective topography of SNc neuronal loss and focal motor onset in PD.
Cortically Driven Onset and Progression of Parkinson's Disease Physiological Corticostriatal Stress According to the proposed cortical pathogenesis, any molecular alteration that disrupts the Ca 2+ -mediated homeostasis of alpha-synuclein at corticostriatal terminals may be relevant for the onset and progression of PD. Nevertheless, the proposed pathogenic mechanism does not necessarily require an explicit cortical dysfunction to initiate the neurodegeneration process. Physiological overuse, leading to functional stress, of corticostriatal motor projections during continuous engagement of various habitual behaviors may be sufficient to ''push over the edge'' the most vulnerable nigrostriatal terminals (Herná ndez et al., 2015) . Importantly, the idea of corticostriatal stress should by no means be interpreted against the beneficial impact of aerobic exercise in PD (Mak et al., 2017; Ahlskog, 2018) , which is likely mediated by mechanisms beyond corticostriatal activity, such as systemic increase of brain-derived neurotrophic (D) Striatal staining of vesicular monoamine transporter (VMAT2) in non-transgenic mice (NonTg) and in transgenic mice overexpressing alpha-synuclein (A53T), after increasing dopamine levels in the striatum by injection of lentiviral vector containing the gene encoding human tyrosine hydroxylase (TH) with mutation of R 37 R 38 to E 37 E 38 (TH-RREE), relative to empty-vectorinjected controls (CtrlVect). High levels of striatal dopamine and alpha-synuclein ultimately lead to nigrostriatal neurodegeneration. From Mor et al. (2017) , with permission (Nat. Neurosci., Springer Nature).
factor (Graziano et al., 2013; Hirsch et al., 2018) . Still, the concept of physiological corticostriatal stress remains hypothetical, and the possibility that daily life activities-e.g., jobs with high complexity and demands (Valdé s et al., 2014; Sieurin et al., 2018) -may influence the incidence of PD by increasing habitual behaviors and overloading corticostriatal circuits will require further investigation. Cortical Pathogenic-Pathophysiological Interaction Whether at cortical level pathogenic alterations precede or follow pathophysiological alterations in PD might be a classical chicken-or-egg problem. Bidirectional pathogenic-pathophysiological interaction seems a more likely scenario. Cortical pathophysiological alterations developing in the motor circuit as a consequence of the initial dopaminergic dysfunction would thus affect corticostriatal activity and may become a top-down pathogenic booster for the striatal somatotopic progression of the disease. In fact, exaggerated corticostriatal activity is well described in animal models of dopamine depletion, and indirectly in patients with PD, in the form of excessive beta oscillations during wakefulness and abnormal slow-wave activity during sleep (Priori et al., 2004; Hammond et al., 2007; Oswal et al., 2016; Sharott et al., 2017) . Abnormal corticostriatal oscillations might disrupt the homeostasis of striatal dopamine and alpha-synuclein, boost striatal alpha-synuclein release, and contribute to the neurodegenerative process in PD.
Admittedly, the cortical pathogenic mechanism proposed here is restricted and limited to nigrostriatal neurodegeneration and, therefore, needs to be put in the perspective of the widespread pathology besides nigrostriatal projections now recognized in PD. In this regard, extending the corticostriatal pathogenic-pathophysiological interaction beyond motor areas may help explaining the early development of non-motor symptoms in PD, particularly cognitive impairment (Chahine et al., 2016; Weintraub et al., 2017; Darweesh et al., 2017) .
Integrating the Cortical Pathogenic Theory with Braak's Data
The cortical pathogenic theory presented here postulates the existence of top-down corticostriatal processes that drive retrograde nigrostriatal degeneration. According to Braak's bottom-up progression, patients with Parkinson's disease (Braak's stage R III) typically display Lewy pathology not only in the dopaminergic neurons of the SNc, but also in other structures and cell types, including the olfactory bulb and caudal brainstem (Braak et al., 2003) , the spinal cord (Del Tredici and Braak, 2012) , and peripheral nervous system (Sá nchez-Ferro et al., 2015; Sprenger et al., 2015; Stokholm et al., 2016) . Could cortical pathogenic processes also contribute to the more caudal pathological findings in patients with Parkinson's disease?
If pathogenic cortical activity propagates through corticostriatal projections, it could also propagate through corticospinal and corticobulbar projections of the pyramidal tract. The diversity and complexity of pyramidal tract projections in humans are not fully characterized (Shepherd, 2013 (Shepherd, , 2014 Smith et al., 2014b) . Nevertheless, rat studies suggest that most corticostriatal inputs to medium spiny neurons projecting to the indirect pathway come from axon collaterals of pyramidal tract neurons (Lei et al., 2004) , which also send collaterals to multiple sub-cortical targets (Kita and Kita, 2012; Figure 4A ). Hypothetically moving retrogradely from the spinal cord along corticospinal axons, we would encounter collateral branch connections with the key structure affected from Braak' , leading to secretion of alpha synuclein in the striatal extracellular space. Both extracellular alpha-synuclein and corticostriatal activity promote nigrostriatal dopamine release, respectively by activating via pre-synaptic Ca v 2.2 channels and nicotininc receptors, via cholinergic interneurons (ChI), on dopaminergic axons. Excessive extracellular alpha-synuclein pathologically aggregates at vulnerable dopaminergic synapses, initiating retrograde nigrostriatal degeneration.
Interestingly, the dorsal vagal complex receives direct dopaminergic innervation from the SNc (Anselmi et al., 2017) , and may act as a relay for dopaminergic dysfunction and alpha-synuclein transmission from the central nervous system to the peripheral enteric system (Ulusoy et al., 2017; Garrido-Gil et al., 2018) . More rostral collateral branch connections of the corticospinal tract lead to the serotonergic nucleus raphe magnum (Antal, 1984; rat) and the reticular formation (Humphrey et al., 1978; Keizer and Kuypers, 1989; monkey) , particularly the gigantocellular reticular nucleus (Martinez et al., 1995; cat) , which are key neuromodulatory nuclei in the brainstem affected from Braak's stage II, and are probably responsible for REM sleep behavior disorder (Valencia Garcia et al., 2018) . The noradrenergic locus coeruleus, which is also affected at Braak's stage II, receives direct excitatory projections from more frontal cortical areas (Jodo et al., 1998) . Importantly, toxic alpha-synuclein oligomers are kinetically stabilized by all catecholamines, not only by dopamine (Conway et al., 2001 ). Accordingly, we can conceive a mechanism whereby the long myelinated corticofugal axons might increase extracellular levels of alpha-synuclein via cortically driven activity (Yamada and Iwatsubo, 2018) , ultimately promoting/facilitating aggregation and formation of Lewy bodies at the target structures.
In this regard it is noteworthy, albeit not too often taken into consideration, that for about 50% of PD patients the anatomical evolution of Lewy pathology does not follow the postulated bottom-up progression (Kalaitzakis et al., 2008) . Two recent studies in rodents and non-human primates have revealed that alpha-synuclein + aggregates may also spread from brain to gut (Ulusoy et al., 2017; Dovero et al., 2017, Soc. Neurosci., abstract) , indicating a possible ''two-way traffic'' for toxic species underlying Lewy pathology and its putative detrimental effect. Thus, a dual pathogenic mechanism of spread may actually result in a more comprehensive and realistic picture for PD in general. For any given patient, which mechanism may be more relevant and significant will probably depend on individual vulnerability factors and on the ''pathological threshold'' of each structure (Engelender and Isacson, 2017) . Overall, both bottom-up and top-down pathogenic mechanisms may contribute to the onset and progression of PD ( Figure 4B ).
Conclusions
The clinical paradox of a focal onset of motor signs caused by the neurodegeneration of a non-somatotopic structure led us (A) Representative pyramidal tract neurons reconstructed after injection of biotinylated dextran amine in the rat motor cortex. The traced neurons emit axon collaterals (shown with different colors) to multiple subcortical structures throughout their route to the midbrain and spinal cord. AGl, lateral agranular cortex; AGm, medial agranular cortex; cp, cerebral peduncle; GPe, Globus pallidus externus; Gr, granular cortex; ic, internal capsule; IO, inferior olive; lfp, longitudinal fasciculus of the pons; ot, optic tract; Gi, gigantocellular reticular nucleus; ot, optic tract; PnO, pontine reticular nucleus, oral part; py, medullary pyramid; pyd, pyramidal decussation; Rt, reticular thalamic nucleus; Str, striatum; VM, ventromedial thalamic nucleus. From Kita and Kita (2012) , with permission. (B) Corticospinal and corticobulbar projections forming the pyramidal tract originate from a vast set of cortical regions-spanning at least from the supplementary motor complex to the superior parietal lobule-and leave a rich network of projections and collaterals in brainstem structures that are affected at early Braak's stages. Modified from Braak et al. (2003) , with permission. Top-down and bottom-up pathogenic mechanisms can in principle coexist.
to turn our attention to the gold standard of somatotopy: the neocortex. A cortical pathogenesis of Parkinson's disease offers a viable solution-admittedly not the only possible one-to this anatomo-clinical dissociation. The proposed cortical pathogenic theory is built upon the increasing amount of evidence documenting cortical involvement in the early and prodromal stages of Parkinson's disease. Importantly, even though our top-down theory might seem a radical alternative to Braak's theory of bottom-up progression (Braak et al., 2003) , it is in fact fully compatible with Braak's experimental data. Both theories presently lack causal evidence and have similar methodological limitations (Surmeier et al., 2017) . Furthermore, the two theories are not mutually exclusive, in the sense that bottom-up and top-down mechanisms can in principle coexist, possibly explaining the increasingly recognized complexity of predominant phenotypes and evolutions of Parkinson's disease Kalia and Lang, 2015) . Our conceptual effort might thus contribute to a more complete and balanced epistemological framework for interpreting old data and designing new experiments. These experiments will be necessary to establish whether the cortex may be a realistic target for future diseasemodifying therapies. At the very least, we hope that our cortical pathogenic theory will add a thought-provoking top-down perspective to the quest for understanding the stress factors that contribute to the vulnerability of SNc dopaminergic cells in the onset and progression of Parkinson's disease.
